Novel methods of treating hearing loss
US-2024390323-A1 · Nov 28, 2024 · US
US9737494B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9737494-B2 |
| Application number | US-201514676265-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 1, 2015 |
| Priority date | May 15, 2012 |
| Publication date | Aug 22, 2017 |
| Grant date | Aug 22, 2017 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Disclosed are a method of preparation and method of application of a circadian rhythm regulatory agent having as an active ingredient an alkylresorcinol represented by general formula (I) below and a circadian rhythm regulatory agent containing as an active ingredient an alkylresorcinol-containing extract from a cereal or a nut containing an alkylresorcinol of the following general formula (I). In the following general formula (I), R 1 is a saturated or unsaturated alkyl group; and R 2 is hydrogen or methyl. In general formula (I), R 1 is preferably at the para-position with respect to R 2 , and R 1 is preferably a saturated or unsaturated alkyl group having 15 to 27 carbon atoms. [Chem. 1]
Opening claim text (preview).
The invention claimed is: 1. A method of regulating the circadian rhythm of a human, comprising steps of: providing a pharmaceutical composition, comprising as an active ingredient a plant extract comprising an alkylresorcinol of general formula (1): wherein R 1 is a saturated or unsaturated C15-C27 alkyl group; and R 2 is a hydrogen atom or a methyl group; and administering to said human an effective amount in a range of 0.01 to 10 g per day of the pharmaceutical composition. 2. The method according to claim 1 , wherein the plant extract comprises a combination of: 1,3-Dihydroxy-5-n-pentadecylbenzene, 1,3-Dihydroxy-5-n-heptadecylbenzene, 1,3-Dihydroxy-5-n-nonadecylbenzene, 1,3-Dihydroxy-5-n-heneicosylbenzene, 1,3-Dihydroxy-5-n-tricosylbenzene, and 1,3-Dihydroxy-5-n-pentacosylbenzene.
Dihydroxy benzenes; Alkylated derivatives thereof · CPC title
Hypnotics; Sedatives · CPC title
for peripheral neuropathies · CPC title
involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones · CPC title
Magnoliopsida (dicotyledons) · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.